David Kudrow, MD

Dr David Kudrow shares some advice for community neurologists on the acute and preventive treatment of migraine.

A key opinion leader illustrates how recently approved rimegepant for preventive episodic migraine treatment could change the treatment landscape.

David Kudrow, MD, reviews the available FDA-approved injectable CGRP antagonists for preventive migraine treatment.

A migraine specialist examines the efficacy and safety of oral CGRP antagonist ubrogepant for the acute treatment of migraine.

Dr David Kudrow discusses how CGRP antagonist treatments have affected chronic migraine, including the effect on quality of life.

An expert neurologist explains how to decide on migraine treatment with a patient and when to consider preventive treatment.

David Kudrow, MD, defines episodic and chronic migraine and details how symptoms differ.